Physician profile
Tracey Morran
NPI 1972087542
$7,354.86
in general payments reported to CMS, 2019-2025
30 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,014 · 2022: $1,191 · 2023: $1,427 · 2024: $1,481 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,149.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,859.16 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,135.28 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $923.19 | 2021-2025 | Xifaxan, Relistor |
| Pfizer INC. | $582.86 | 2021-2025 | |
| Janssen Biotech, INC. | $399.40 | 2021-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $314.27 | 2021-2025 | Livdelzi |
| Regeneron Healthcare Solutions, INC. | $232.44 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $230.28 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $222.19 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $187.19 | 2024-2025 | Zenpep, Vowst |
| Celgene Corporation | $160.23 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $144.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $112.44 | 2022-2025 | Rebyota |
| Qol Medical, LLC | $110.88 | 2021-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $95.37 | 2022-2024 | Dificid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $90.75 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $78.78 | 2022-2023 | Ibsrela |
| Amgen INC. | $76.53 | 2021-2023 | Avsola, Amjevita |
| Genzyme Corporation | $63.30 | 2022-2023 | |
| Novo Nordisk INC | $44.83 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $44.64 | 2021-2022 | |
| Braintree Laboratories, INC. | $42.68 | 2021-2024 | Sutab, Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.39 | 2023 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $30.88 | 2021 | |
| Redhill Biopharma INC. | $25.58 | 2021 | |
| Organon LLC | $25.17 | 2024 | |
| Biocon Biologics INC | $24.50 | 2025 | Yesintek |
| Celltrion USA INC. | $24.14 | 2024 | Zymfentra |
| Fresenius Kabi USA, LLC | $17.51 | 2023 | |
| Phadia US INC. | $14.56 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Morran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.